| Income Statement | 2025-09-30 | |||
|---|---|---|---|---|
| Revenue | 13,120 | |||
| Cost of revenue | 3,349 | |||
| Gross profit (deficit) | 9,771 | |||
| Research and development | 28,846 | |||
| Acquired in-process research and development | 0 | |||
| Selling, general and administrative | 37,359 | |||
| Total operating expenses | 66,205 | |||
| Loss from operations | -56,434 | |||
| Interest income | 6,033 | |||
| Interest expense | 6,534 | |||
| Investment advisory fees | 171 | |||
| Change in fair value of warrant liability | -612 | |||
| Realized (loss) gain on marketable securities | 0 | |||
| Net gain (loss) on disposal of fixed assets | 4 | |||
| Other income | 698 | |||
| Total other income, net | 642 | |||
| Loss before income taxes | -55,792 | |||
| Provision for income taxes | 0 | |||
| Net loss | -55,792 | |||
| Currency translation adjustment | 313 | |||
| Change in unrealized gain (loss) on available-for-sale securities | 501 | |||
| Comprehensive loss | -55,604 | |||
| Net loss per share attributable to common stockholders, basic | -0.16 | |||
| Net loss per share attributable to common stockholders, diluted | -0.16 | |||
| Weighted average common shares outstanding, basic | 342,393 | |||
| Weighted average common shares outstanding, diluted | 342,393 | |||
Nuvation Bio Inc. (NUVB-WT)
Nuvation Bio Inc. (NUVB-WT)